Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 980-988

  Luty, Adrian J F ^a   Lell, Bertrand ^b   Schmidt Ott, Ruprecht ^b   Lehman, Leopold G ^b   Luckner, Doris ^b   Greve, Bernhard ^b   Matousek, Peter ^b   Herbich, Klaus ^b   Schmid, Daniela ^b   Migot Nabias, Florence ^b   Deloron, Philippe ^b   Nussenzweig, Ruth S ^b   Kremsner, Peter G ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PARASITE ANTIGEN; TUMOR NECROSIS FACTOR;

AFRICA; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; HELPER CELL; HUMAN; IMMUNOREACTIVITY; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALARIA; MEROZOITE; MONONUCLEAR CELL; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REINFECTION; SPOROZOITE;

EID: 0032948127     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314689     Document Type: Article

References (60)

1. Marsh K, Hayes RH, Carson DC, et al. Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population. Trans R Soc Trop Med Hyg 1988; 82:532-7.
2. Hoffman SL, Oster CN, Mason C, et al. Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J Immunol 1989; 142:1299-303.
3. Hollingdale MR, Hogh B, Petersen E, Wirtz RA, Bjorkmann A. Age-dependent occurrence of protective anti-Plasmodium falciparum sporozoite antibodies in a holoendemic area of Liberia. Trans R Soc Trop Med Hyg 1989; 83:322-4.
4. Snow RW, Shenton FC, Lindsay SW, et al. Sporozoite antibodies and malaria in children in a rural area of The Gambia. Ann Trop Med Parasitol 1989; 83:559-68.
5. Riley EM, Allen SJ, Bennett S, et al. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans R Soc Trop Med Hyg 1990; 84:648-57.
6. Marsh K, Otoo L, Hayes RH, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293-303.
7. Riley EM, Allen SJ, Wheeler JG, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSPI) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992; 14:321-37.
8. Tolle R, Früh K, Doumbo O, et al. A prospective study of the association between the human humoral response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun 1993; 61:40-7.
9. Al-Yaman F, Genton B, Anders RF, et al. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg 1994; 51:593-602.
10. Al-Yaman F, Genton B, Kramer KJ, et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 1996; 54:443-8.
11. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium fulciparum malaria is associated with serum antibodies to the 19-kDa C- terminal fragment of the merozoite surface antigen. PfMSP-1. J Infect Dis 1996; 173:765-9.
12. Chougnet C, Lepers JP, Astagneau P, Rason MD, Savel J, Deloron P. Lymphoproliferative responses to synthetic peptides from merozoite ring-infected erythrocyte surface antigen and circumsporozoite protein: a longitudinal study during a falciparum malaria episode. Am J Trop Med Hyg 1991; 45:560-6.
13. Riley EM, Allen SJ, Troye-Blomberg M, et al. Association between immune recognition of the malaria vaccine candidate antigen Pf155/RESA and resistance to clinical disease: a prospective study in a malaria endemic region of West Africa. Trans R Soc Trop Med Hyg 1991; 85:436-43.
14. Riley EM, Jakobsen PH, Allen SJ, et al. Immune response to soluble exoantigens of Plasmodium falciparum may contribute to both pathogenesis and protection in clinical malaria: evidence from a longitudinal, prospective study of semi-immune African children. Eur J Immunol 1991; 21: 1019-25.
15. Mshana RN, Boulandi J, Mayombo J, Mendome G. In vitro lymphoproliferative responses to malaria antigens: a prospective study of residents of a holoendemic area with perennial malaria transmission. Parasite Immunol 1993; 15:35-45.
16. Al-Yaman F, Genton B, Taraika J, Anders R, Alpers MP. Cellular immunity to merozoite surface protein 2 (FC27 and 3D7) in Papua New Guinean children. Temporal variation and relation to clinical and parasitological status. Parasite Immunol 1997; 19:207-14.
17. Al-Yaman F, Genton B, Taraika J, Anders R, Alpers MP. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. Parasite Immunol 1997; 19:249-54.
18. Hill AVS, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434-9.
19. Fidock DA, Gras MH, Lepers JP, et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994; 153:190-204.
20. Brasseur P, Ballet JJ, Druilhe P. Impairment of Plasmodium falciparum specific antibody response in severe malaria. J Clin Microbiol 1990; 28:265-8.
21. Erunkulu OA, Hill AVS, Kwiatkowski DP, et al. Severe malaria in Gambian children is not due to lack of previous exposure to malaria. Clin Exp Immunol 1992; 89:296-300.
22. Grau GE, Taylor TE, Molyneux MR, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989; 320: 1586-91.
23. Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor-α and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989; 87:139-43.
24. Kwiatkowski D, Hill AVS, Sambou I, et al. TNF concentration in cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990; 336:1201-4.
25. Mshana RN, Boulandi J, Mshana KM, Mayombo J, Mendome G. Cytokines in the pathogenesis of malaria: levels of IL-Iβ, IL-4, IL-6, TNF-α and IFN-γ in plasma of healthy individuals and malaria patients in a holoendemic area. J Clin Lab Immunol 1991; 34:131-9.
26. Ringwald P, Peyron F, Vuillez JP, Touze JE, Le Bras J, Deloron P. Levels of cytokines in plasma during Plasmodium falciparum malaria attacks. J Clin Microbiol 1991; 29:2076-8.
27. Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J. High levels of circulating IL-10 in human malaria. Clin Exp Immunol 1994; 95:300-3.
28. Ho M, Sexton MM, Tongtawe P, Looareesuwan S, Suntharasamai P, Webster HK. Interleukin-10 inhibits tumor necrosis factor production but not antigen-specific lymphoproliferation in acute Plasmodium falciparum malaria. J Infect Dis 1995; 172:838-44.
29. Kremsner PG, Winkler S, Brandts C, et al. Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am J Trop Med Hyg 1995; 53:532-8.
30. Mordmuller BG, Metzger WG, Juillard P, et al. Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance. Eur Cytokine Netw 1997; 8:29-35.
31. Marsh K. Malaria - a neglected disease? Parasitology 1992; 104:S53-69.
32. Kun JFJ, Schmidt-Ott RJ, Lehman LG, et al. Merozoite surface antigen 1 and 2 genotypes and rosetting of Plasmodium falciparum in severe and mild malaria in Lambarene, Gabon. Trans R Soc Trop Med Hyg 1998; 92:110-4.
33. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Wiedermann G. A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis 1988; 158:1368-71.
34. Munesinghe DY, Clavijo P, Calvo Calle M, Nussenzweig RS, Nardin EH. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. Eur J Immunol 1991; 21:3015-20.
35. de Oliveira GA, Clavijo P, Nussenzweig RS, Nardin EH. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T- cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application. Vaccine 1994; 12:1012-7.
36. Rzepczyk CM, Csurhes PA, Saul AJ, et al. Comparative study of the T cell response to two allelic forms of a malarial vaccine candidate protein. J Immunol 1992; 148:1197-204.
37. Kabilan L, Sharma VP, Kaur P, Ghosh SK, Yadav RS, Chauhan VS. Cellular and humoral immune responses to well-defined blood stage antigens (major merozoite surface antigen) of Plasmodium falciparum in adults from an Indian zone where malaria is endemic. Infect Immun 1994; 62:685-91.
38. Yang C, Shi YP, Udhayakumar V, et al. Sequence variations in the nonrepetitive regions of the liver stage-specific antigen-1 of Plasmodium falciparum from field isolates. Mol Biochem Parasitol 1995; 71:291-4.
39. Luty AJF, Mayombo J, Lekoulou F, Mshana R. Immunologic responses to soluble exoantigens of Plasmodium falciparum in Gabonese children exposed to continuous intense infection. Am J Trop Med Hyg 1994; 51: 720-9.
40. Menendez C, Kahigwa E, Hirt R, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997; 350: 844-50.
41. Stoltzfus RJ. Rethinking anaemia surveillance. Lancet 1997; 349:1764-6.
42. Kun JFJ, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998; 351:265-6.
43. Hviid L, Kurtzahls JAL, Goka BQ, Oliver-Commey JO, Nkrumah FK, Theander TG. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun 1997; 65:4090-3.
44. Brasseur P, Agrapart M, Ballet JJ, Druilhe P, Warrell MJ, Tharavanij S. Impaired cell-mediated immunity in Plasmodium falciparum infected patients with high-parasitemia and cerebral malaria. Clin Immunol Immunopathol 1983; 27:38-50.
45. Riley EM, Andersson G, Otoo LN, Jepsen S, Greenwood BM. Cellular immune responses to Plasmodium falciparum antigens during and after an acute attack of falciparum malaria. Clin Exp Immunol 1988; 73:17-22.
46. Kremsner PG, Zotter GM, Feldmeier H, et al. Immune response in patients during and after Plasmodium falciparum infection. J Infect Dis 1990; 161: 1025-8.
47. Chougnet C, Tallet S, Ringwald P, Deloron P. Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum attack. Clin Exp Immunol 1992; 90:405-8.
48. Luckner D, Lell B, Greve B, et al. No influence of socio-economic factors on severe malarial anaemia, hyper-parasitaemia and reinfection. Trans R Soc Trop Med Hyg 1998; 92:478-81.
49. Guerin-Marchand C, Druilhe P, Galey B, et al. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987; 329:164-7.
50. Connelly M, King CL, Bucci K, et al. T-cell immunity to peptide epitopes of liver-stage antigen-1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun 1997; 65:5082-7.
51. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664-8.
52. + T cells. J Exp Med 1994; 180:353-8.
53. Klotz FW, Scheller LF, Seguin MC, et al. Co-localization of inducible nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J Immunol 1995; 154:3391-5.
54. Ferreira A, Schofield L, Enea V, et al. Inhibition of development of exoerythrocytic forms of malaria parasites by γ-interferon. Science 1986; 232: 881-4.
55. Deloron P, Chougnet C, Lepers JP, Tallet S, Coulange P. Protective value of elevated levels of γ interferon in serum against exoerythrocytic stages of Plasmodium falciparum. J Clin Microbiol 1991; 29:1757-60.
56. Chizzolini C, Grau GE, Geinoz A, Schrijvers D. T lymphocyte interferon-γ production induced by Plasmodium falciparum antigen is high in recently infected non-immune and low in immune subjects. Clin Exp Immunol 1990; 79:95-9.
57. Bouharoun-Tayoun H, Oevray C, Lund F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
58. Druilhe P, Perignon JL. A hypothesis about the chronicity of malaria infection. Parasitol Today 1997; 13:353-7.
59. Kumaratilake LM, Ferrante A. T-cell cytokines in malaria: their role in the regulation of neutrophil- and macrophage-mediated killing of Plasmodium falciparum asexual blood forms. Res Immunol 1994; 145:423-9.
60. Taylor-Robinson AW. Regulation of immunity to malaria. Valuable lessons learned from murine models. Parasitol Today 1995; 11:334-42.